Emily Black, MD
Clinical Genetics (M.D.) · Greenville, SCNPI 1053730838
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $489 of the $549 with a category attached, or 89.1%. 9 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 41.4% of the total. Reporting peaked in 2024 at $348 and has fallen 52.6% since, to $165 in 2025.
Across 21 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$227
- Sanofi$109
- Cycle Pharmaceuticals Inc$53
- PTC Therapeutics, Inc.$52
- Chiesi USA, Inc.$27
- Zevra Therapeutics Inc$22
- plus $59 from 3 others
Across 10 payments — averaging $877.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$9K
What the payments were for
- Consulting fees$224%
- Food & beverage$48989%
- Education$387%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 6 | $227 |
| Sanofi | 5 | $109 |
| Cycle Pharmaceuticals Inc | 3 | $53 |
| PTC Therapeutics, Inc. | 2 | $52 |
| Chiesi USA, Inc. | 1 | $27 |
| Zevra Therapeutics Inc | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
How this compares
Too few clinical genetics (m.d.) providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other clinical genetics (m.d.) in Greenville
- Richard RogersGreenville$400K
- David EvermanGreenville$186
- Neena ChampaigneCharleston$31K
- Kristen LancasterCharleston$6K
- Steven SkinnerGreenwood$6K
- Michael LyonsNorth Charleston$501
- Steven ShapiroCharleston$470
- Elliot StolermanNorth Charleston$452
- Richard SchroerNorth Charleston$393
- Sara CatheyNorth Charleston$307
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.